Video Upload Options

References

1. Astuti D, Latif F, Dallol A, Dahia PL, Douglas F, George E, Sköldberg F,Husebye ES, Eng C, Maher ER. Gene mutations in the succinate dehydrogenasesubunit SDHB cause susceptibility to familial pheochromocytoma and to familialparaganglioma. Am J Hum Genet. 2001 Jul;69(1):49-54.in: Am J Hum Genet 2002 Feb;70(2):565.
2. Bayley JP, Kunst HP, Cascon A, Sampietro ML, Gaal J, Korpershoek E,Hinojar-Gutierrez A, Timmers HJ, Hoefsloot LH, Hermsen MA, Suárez C, Hussain AK, Vriends AH, Hes FJ, Jansen JC, Tops CM, Corssmit EP, de Knijff P, Lenders JW,Cremers CW, Devilee P, Dinjens WN, de Krijger RR, Robledo M. SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. Lancet Oncol. 2010Apr;11(4):366-72. doi: 10.1016/S1470-2045(10)70007-3.
3. Burnichon N, Rohmer V, Amar L, Herman P, Leboulleux S, Darrouzet V, Niccoli P,Gaillard D, Chabrier G, Chabolle F, Coupier I, Thieblot P, Lecomte P, BertheratJ, Wion-Barbot N, Murat A, Venisse A, Plouin PF, Jeunemaitre X, Gimenez-Roqueplo AP; PGL.NET network. The succinate dehydrogenase genetic testing in a largeprospective series of patients with paragangliomas. J Clin Endocrinol Metab. 2009Aug;94(8):2817-27. doi: 10.1210/jc.2008-2504.
4. Chetty R. Familial paraganglioma syndromes. J Clin Pathol. 2010Jun;63(6):488-91. doi: 10.1136/jcp.2010.076257. Review.
5. Crona J, Taïeb D, Pacak K. New Perspectives on Pheochromocytoma andParaganglioma: Toward a Molecular Classification. Endocr Rev. 2017 Dec1;38(6):489-515. doi: 10.1210/er.2017-00062. Review.
6. Douwes Dekker PB, Hogendoorn PC, Kuipers-Dijkshoorn N, Prins FA, van DuinenSG, Taschner PE, van der Mey AG, Cornelisse CJ. SDHD mutations in head and neckparagangliomas result in destabilization of complex II in the mitochondrialrespiratory chain with loss of enzymatic activity and abnormal mitochondrialmorphology. J Pathol. 2003 Nov;201(3):480-6.
7. Else T, Greenberg S, Fishbein L. Hereditary Paraganglioma-PheochromocytomaSyndromes. 2008 May 21 [updated 2018 Oct 4]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet].Seattle (WA): University of Washington, Seattle; 1993-2020. Available fromhttp://www.ncbi.nlm.nih.gov/books/NBK1548/
8. Gimenez-Roqueplo AP, Favier J, Rustin P, Mourad JJ, Plouin PF, Corvol P, RötigA, Jeunemaitre X. The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratorychain and activates the hypoxia pathway. Am J Hum Genet. 2001 Dec;69(6):1186-97.
9. Gimenez-Roqueplo AP, Favier J, Rustin P, Rieubland C, Crespin M, Nau V, KhauVan Kien P, Corvol P, Plouin PF, Jeunemaitre X; COMETE Network. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res. 2003 Sep 1;63(17):5615-21.
10. Hao HX, Khalimonchuk O, Schraders M, Dephoure N, Bayley JP, Kunst H, DevileeP, Cremers CW, Schiffman JD, Bentz BG, Gygi SP, Winge DR, Kremer H, Rutter J.SDH5, a gene required for flavination of succinate dehydrogenase, is mutated inparaganglioma. Science. 2009 Aug 28;325(5944):1139-42. doi:10.1126/science.1175689.
11. Müller U. Pathological mechanisms and parent-of-origin effects in hereditaryparaganglioma/pheochromocytoma (PGL/PCC). Neurogenetics. 2011 Aug;12(3):175-81.doi: 10.1007/s10048-011-0280-y.
12. Neumann HP, Pawlu C, Peczkowska M, Bausch B, McWhinney SR, Muresan M, BuchtaM, Franke G, Klisch J, Bley TA, Hoegerle S, Boedeker CC, Opocher G, Schipper J,Januszewicz A, Eng C; European-American Paraganglioma Study Group. Distinctclinical features of paraganglioma syndromes associated with SDHB and SDHD genemutations. JAMA. 2004 Aug 25;292(8):943-51. Erratum in: JAMA. 2004 Oct13;292(14):1686.
13. Niemann S, Müller U. Mutations in SDHC cause autosomal dominant paraganglioma,type 3. Nat Genet. 2000 Nov;26(3):268-70.
14. Pasini B, Stratakis CA. SDH mutations in tumorigenesis and inherited endocrinetumours: lesson from the phaeochromocytoma-paraganglioma syndromes. J Intern Med.2009 Jul;266(1):19-42. doi: 10.1111/j.1365-2796.2009.02111.x. Review.
15. Pollard PJ, Brière JJ, Alam NA, Barwell J, Barclay E, Wortham NC, Hunt T,Mitchell M, Olpin S, Moat SJ, Hargreaves IP, Heales SJ, Chung YL, Griffiths JR,Dalgleish A, McGrath JA, Gleeson MJ, Hodgson SV, Poulsom R, Rustin P, TomlinsonIP. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha intumours which result from germline FH and SDH mutations. Hum Mol Genet. 2005 Aug 1;14(15):2231-9.
16. Schiavi F, Boedeker CC, Bausch B, Peçzkowska M, Gomez CF, Strassburg T, Pawlu C, Buchta M, Salzmann M, Hoffmann MM, Berlis A, Brink I, Cybulla M, Muresan M,Walter MA, Forrer F, Välimäki M, Kawecki A, Szutkowski Z, Schipper J, Walz MK,Pigny P, Bauters C, Willet-Brozick JE, Baysal BE, Januszewicz A, Eng C, OpocherG, Neumann HP; European-American Paraganglioma Study Group. Predictors andprevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA. 2005 Oct 26;294(16):2057-63. Erratum in: JAMA. 2006 Feb 8;295(6):628.
17. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, PanY, Simon MC, Thompson CB, Gottlieb E. Succinate links TCA cycle dysfunction tooncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell. 2005Jan;7(1):77-85.